|
|
Pharmaxis Ltd - Comparative Business Analysis Snapshot
Business Description
Pharmaxis Ltd. The Group's principal activities are researching, developing and commercializing human healthcare products for the treatment and management of chronic respiratory and immune disease. Products include Aridol and Bronchitol. Aridol is designed to help doctors diagnose and manage asthma by detecting active airway inflammation through measuring airway hyper-responsiveness. Bronchitol is a drug designed to reduce the amount of mucus build-up in the lungs of patients suffering from chronic respiratory conditions. The Group operates predominantly in Australia.
Competitor Analysis
This analysis compares Pharmaxis Ltd with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for? Click here for more browsing options.
|
|
|
|
|
